Upcoming Studies


Atezolizumab in combination with Bevacizumab and Chemotherapy versus Chemo-Bevacizumab in recurrent ovarian cancer – a randomized Phase III trial

Sponsor: AGO Study Group

Learn More ->


A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator’s Choice Chemotherapy in Secondor Third-Line Recurrent or Metastatic Cervical Cancer

Sponsor: Genmab

Learn More ->


A Phase 3, Randomized, Double‐Blind Study of Pembrolizumab versus Placebo in Combination With
Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High‐Risk Endometrial Cancer After Surgery With Curative Intent

Sponsor: Merck Sharp & Dohme Corp.

Learn More ->


An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204)

Sponsor: Incyte

Participating sites:

  • Institut Jules Bordet, Bruxelles
  • CHU de Liège, site Sart Tilman, Liège
  • UZ Gent, Gent
  • UZ Leuven, Leuven

Learn More ->